Agitation

Earn CME/CE in your profession:


Continuing Education Activity

Agitation is a complex, nonspecific constellation of behaviors observed in various treatment settings. Agitation can pose significant risks to both the agitated individuals and those around them, making it an emergency. Acute presentations of agitation can include restlessness, inability to stay calm, paranoia, suspiciousness, irritability, hostility, confusion, disorientation, inability to communicate, changes in vital signs, and violent behavior. The etiology of agitation is multifactorial and includes neurological, infectious, cardiac, respiratory, psychiatric, toxic or metabolic, endocrine, constitutional, and substance-related causes. The approach to understanding and managing agitation varies based on the setting, individual factors, clinician's experience, and specific etiology. 

Early assessment should include point-of-care glucose, oxygen saturation, and urine toxicology screen. Effective management prioritizes diagnosing and treating acute medical conditions while ensuring the safety of the patient, staff, and environment. Treatment strategies are guided by the specific etiology of agitation and the epidemiology of the local patient population, which may include understanding the prevalence of substance use in the community. This activity reviews the current understanding of the neurobiology of agitation, various causes of behavioral disturbances, diagnostic cues, and management strategies across different settings. This activity also explores the etiology, pathophysiology, risk factors, early assessment, and principles of treatment for this complex condition. This activity highlights the role of the interprofessional healthcare team in managing agitation and provides them with the knowledge necessary to provide optimal care for individuals with agitation, as mismanagement can lead to poor patient outcomes and staff injuries.

Objectives:

  • Identify the signs and symptoms of agitation and recognize its multifactorial etiology, including neurological, psychiatric, and substance-related causes.

  • Implement effective de-escalation techniques and pharmacological interventions tailored to the specific etiology of agitation to ensure patient and staff safety.

  • Apply knowledge of the neurobiology of agitation and current management guidelines to provide evidence-based care and improve patient outcomes.

  • Collaborate with an interprofessional healthcare team, including psychiatry, nursing, and security, to manage agitation comprehensively and safely.

Introduction

Agitation is a nonspecific constellation of behaviors seen in various treatment settings. Agitated individuals can be dangerous to themselves and others, making agitation an emergency. Acute presentations of agitation can include restlessness, inability to stay calm, paranoia, suspiciousness, irritability, hostility, confusion, disorientation, inability to communicate, changes in vital signs, and violent behavior. Agitation can have a multifactorial etiology that is often difficult to identify. Individuals with agitation may present in various settings, including emergency departments, medical units, intensive care units (ICUs), inpatient psychiatry units, outpatient clinics, and long-term care facilities. Approaches to understanding and managing agitation can vary depending on the setting, individual factors, clinician experience, and the underlying etiology. 

Multiple definitions have been offered for agitation, reflecting the complexity of this syndrome. The Diagnostic and Statistical Manual of Mental Disorders, 5th ed.; Text Revision (DSM-5-TR) characterizes agitation as "the inability to sit still, pacing, handwringing; or pulling or rubbing of the skin, clothing, or other objects" and as "disruptive motor or vocal activity." In their evaluation of a new drug application for the treatment of agitation on May 11, 2023, the United States Food and Drug Administration (FDA) Center for Drug Evaluation and Research described agitation as including "symptoms ranging from pacing and restlessness to verbal and physical aggression." The International Experts' Meeting on Agitation in 2016 noted that a consensus on the definition of agitation does not exist and formulated a practical description of agitation as "a state where patients cannot remain still or calm, characterized by internal features such as hyperresponsiveness, racing thoughts, and emotional tension; and external ones, mainly motor and verbal hyperactivity, and communication impairment." [1][2] In dementia, it is helpful to conceptualize aggressive and agitated behavior as "responsive behavior that manifests in response to a stimulus in the patient's internal or external environment." [3]

Agitation can be distinguished from aggression. In individuals with dementia, agitation is described as "a constellation of symptoms, including pacing, aimless wandering, performing repetitious mannerisms, and general restlessness," whereas aggression encompasses "both verbal and physical behavior, such as hitting, kicking, pushing, throwing or tearing things, spitting, biting, scratching, destroying property, grabbing people or objects away from others, hurting oneself or others, making sexual advances, cursing, and screaming." [3] In the broader population, acute agitation is characterized as "a state of unease or inner tension with or without excessive motor activity," while aggression is the "behavioral expression of severe agitation with the potential to cause harm to oneself or others." [4] As the definition and use of the term "agitation" vary, the clinical team should attempt to identify patient-specific behaviors to clarify how agitation is defined for each individual patient. Reaching a consensus on this definition will help direct the management plan effectively.[3] 

In a study of patients with dementia, aggressive behavior was defined as "an overt act involving the delivery of noxious stimuli to (but not necessarily aimed at) another object, organism, or self, which is clearly not accidental." [5] In this population, the prevalence of verbal aggression was 89%, while physical aggression and destructive behavior were 61% and 25%, respectively. Verbal aggression was found to persist for about 2 years, and 67% of individuals with verbal aggression remained verbally aggressive until near death. Physical aggression was found to be self-limiting, lasting for only 1 year. Intimate care was identified as the primary factor precipitating aggressive behavior, with hallucinations and delusions as secondary contributors.[5] 

The proposed hypothesis for this association is that misinterpretation of the environment leads to the perception of intimate care as a threat. This hypothesis is supported by the finding that most aggressive behavior was directed toward a group, primarily primary caregivers. Aggressive behavior resembled the patient's premorbid behavior (behavior before dementia diagnosis) in only 3% of cases. In contrast, 43% of individuals displayed aggression as an "exaggeration of premorbid behavior," while 53% exhibited aggression that was "quite different from premorbid behavior." Aggressive behavior was found to cease before death, with the hypothesized mechanism being progressive cognitive impairment. This impairment likely leads to reduced awareness of the environment and a diminished perception of intimate care as a threat.[6][7]

Etiology

Agitation can be multifactorial, reflecting the interaction between precipitating factors and patient characteristics.[8] In the emergency department, patients may be agitated due to reasons such as intoxication with alcohol or drugs, shock or other metabolic derangements, or exacerbation of psychiatric illness. Quick stabilization is essential to ensure patient and staff safety. In a study, almost 3% of patients presented to the emergency department with agitation, of whom 23% met the criteria for delirium.[9]

The most common conditions that lead to agitation in hospitalized patients are delirium, dementia, and acute psychosis. Delirium develops over a short period, is precipitated by an underlying medical cause or substance intoxication or withdrawal, and is characterized by fluctuations in attention and cognition.[10] One or several co-occurring medical conditions can cause delirium. Predisposing factors for delirium include male gender, older age, cognitive impairment, and metabolic derangements. Precipitating factors include medications such as anticholinergic or psychoactive substances, surgery, hypoxemia and hypoxia, acute pain, and infection.

Delirium is classified into 3 types—hyperactive, hypoactive, and mixed. Agitation in delirium is primarily associated with the hyperactive and mixed subtypes. These subtypes describe the individual's level of psychomotor activity. In hyperactive delirium, psychomotor activity is increased, while in mixed delirium, it fluctuates between increased and decreased (hypoactive) motor activity.[10]

Differentiating delirium from other neurocognitive disorders, such as Alzheimer disease or related dementias (ADRD), is important,  which are characterized by a gradual worsening of cognitive function. Delirium is characterized by rapidly fluctuating mental status with onset in hours to days, whereas dementia involves a gradual deterioration of cognitive function over months to years. Major neurocognitive disorder from ADRD is specified as with or without behavioral disturbances. When delirium and ADRD are comorbid, priority should be given to managing the delirium.

Other etiologies of agitation include traumatic brain injury (TBI), physical pain, acute psychosis or mania in schizophrenia or bipolar spectrum disorders, seizure disorders, autism spectrum disorder, anxiety disorders, acute stress disorder, personality disorders, and sleep-wake cycle disruption.[11][10] Many of these conditions are associated with frontal lobe dysfunction, which is believed to contribute to increased aggressive and agitated behavior.[12][13]

Epidemiology

The epidemiology of agitation varies by age group, etiology, environment, and severity. A large-scale prospective observational study conducted in an urban county emergency department in 2018 found the prevalence of agitation to be 2.6%. Of these patients, 23% met the criteria for delirium. Additionally, 84% of patients with agitation required physical restraint, and 72% required sedation with an intramuscular injection to allow for medical evaluation and to protect both the patient and medical providers from injury.[9] 

A study conducted in 2 urban settings in Germany studied the incidence of prehospital psychiatric emergency situations requiring a second-tier response by an emergency physician. In both urban settings, approximately 12% of all cases were psychiatric emergencies.[14] In one setting, 22.3% of psychiatric emergency calls were for agitation, while in the other setting, 30.1% of psychiatric emergency calls were for agitation. Agitation prevalence ranges from 30% to 50% in Alzheimer disease, 30% in Lewy body disease, 40% in frontotemporal degeneration, and 40% in vascular disease. In nursing homes, 80% of residents experience agitation.[15] A 2018 study in the Netherlands observed the progression of neuropsychiatric symptoms in patients with young-onset dementia, defined as the onset of symptoms before the age of 65, residing in nursing homes. Over the course of 2 years, 52% of young-onset dementia patients developed agitation.[16] 

The incidence of agitation in the ICU is estimated to be between 17.5% and 72%.[17][18][19] Agitation is associated with prolonged ICU stays, mechanical ventilation, unplanned venous catheter removals, unplanned extubations, and nosocomial infections. Independent risk factors for agitation in the ICU include the use of psychoactive drugs at the time of admission, a history of alcohol use disorder, abnormal sodium levels, sepsis, fever, and sedative administration in the ICU.[19] 

Among patients with bipolar disorder and schizophrenia, a 2018 cross-sectional study conducted in Europe found that the majority of agitation episodes in the prior year were either mild or moderate in intensity (22.4% and 15.4%, respectively).[20] The intensity of episodes was characterized through self-report, using a predefined list of symptoms. Two-thirds of patients demonstrated insight and awareness of their agitation. The most commonly reported symptoms during an episode of agitation were feeling uneasy, restlessness, and nervousness.[20]

Between 2007 and 2016, about 8.4 million (8.3%) of 100.9 million emergency department visits in the United States were for psychiatric or substance-use–related diagnoses, with the percentage generally increasing over time.[21] Substance use is a significant risk factor for agitation. The lifetime prevalence of substance use disorders among patients with bipolar disorder is estimated to be 48% to 61%, and among patients with schizophrenia, it is estimated to be 47%.[22] The lifetime prevalence of a substance use disorder in the general community sample of this study was 17%. Substance use, including cannabis, stimulants, opioids, sedatives, and hallucinogens, is independently associated with an increased risk of violent behavior.[23] This risk has been estimated to be 4 to 10 times higher compared to the general population.

Agitation is reported in 20% to 41% of patients with TBIs in acute care units during the early recovery period, rising to 70% in rehabilitation settings.[24] The point prevalence of agitation in patients with intellectual disabilities is reported to be approximately 10%, with a remission rate of 25% at 2 years.[25] Increased risk of medium to high levels of aggression is associated with factors such as younger age, longer behavioral episodes, psychotropic medication use, pervasive developmental disorder, mood instability and irritability, increased contact with mental health professionals, and the need for home care. Several of these risk factors indirectly reflect the severity of the patient’s baseline condition. Personality disorders and longer length of behavioral episodes are associated with adverse clinical outcomes, along with agitation during behavioral episodes and more frequent contact with mental health professionals. In contrast, pervasive developmental disorder is associated with improved clinical outcomes.[25]

Pathophysiology

The neuroanatomy and neurophysiology of agitation involve several brain pathways and regions. Positron-emission tomography (PET) scans in patients with personality disorders and anxiety have highlighted frontal lobe dysfunction as a primary contributor to agitation.[26][27] Restlessness has been associated with disturbances in the limbic and striatal sensorimotor pathways, which leads to the excitation of prefrontal and sensorimotor cortices and the subsequent motor expression of restlessness in the form of agitation.[28] This bottom-up activation occurs in the setting of insufficient top-down inhibition and control normally exerted by higher cortical regions.[29] 

Insufficient amygdalar modulation by higher cortical regions and subsequent hyperactivity can lead to overestimating threats and misinterpreting environmental stimuli. External stress can contribute to the activation of these pathways by reducing inhibition from the prefrontal cortex. Additionally, disordered modulation between the prefrontal cortex and the locus coeruleus locus coeruleus has also been implicated, leading to increased tonic activity of the locus coeruleus and subsequent increased norepinephrine release.[29] 

Dementia may also lead to overactivity of norepinephrine due to compensatory mechanisms. In dementia, progressive loss of neurons in the locus coeruleus and the subsequent decrease in norepinephrine release are thought to lead to compensatory upregulation of adrenergic receptors and hypersensitivity.[15] Abnormal activation of the orbitofrontal cortex and anterior cingulate cortex has been observed in patients with Alzheimer dementia.[15] In postmortem studies of patients with Alzheimer dementia, tau pathology has been associated with neuropsychiatric symptoms, including aggressive behavior.

Multiple neurotransmitters have been postulated to be associated with aggression. Norepinephrine is implicated in aggression, as it is thought to be involved in the hyperactivation of the amygdala and other pathways involved in the "fight-or-flight" response. In addition to norepinephrine, dysregulation of dopaminergic, serotonergic, cholinergic, androgenic, and γ-aminobutyric acid (GABA) systems has also been implicated in aggression.[29] Low levels of 5-hydroxyindoleacetic acid (5-HIAA), a metabolite of serotonin, in the cerebrospinal fluid have been associated with aggressive personality traits as well as suicide attempts using more violent means.[30][31] A meta-analysis from 2020 showed that testosterone was associated with aggression, and it also found a small but statistically significant association between higher endogenous testosterone levels and aggression in men, but not in women.[32]

The neurotransmitters involved in agitation can vary depending on the diagnosis.[28] In psychosis and substance use, particularly stimulant-induced psychosis, agitation is often associated with a hyperdopaminergic state, with increased norepinephrine and reduced GABAergic tone. Dysregulated glutaminergic neurotransmission has also been implicated in agitation in psychosis, as glutamine is considered to modulate dopamine neurotransmission.

Akathisia can lead to agitation and is believed to be modulated by increased dopamine blockade in striatal neurons due to antipsychotic medications, which also elevate central norepinephrine and further antagonize dopamine function.[33] Increased norepinephrine tone and decreased GABAergic inhibition have been proposed as contributing factors to agitation in panic disorder and generalized anxiety disorder. Agitation in these conditions is closely related to anxiety, which may be secondary to heightened hypothalamic-pituitary-adrenal axis activity.

Two different serotonin models of agitation have been proposed in affective disorders.[28] The "serotonin-sensitive" model applies to agitated depression or mania, where high catecholamine levels correspond with low serotonin levels. The "serotonin-resistant" model is characterized by extremely high arousal that drives aggression and agitation, associated with decreased GABAergic function and increased noradrenergic activity. GABA and serotonin pathways, which develop together, are involved in top-down modulation of the limbic system from the cortex, influencing agitation and other dysphoric reactions to the environment.[29]

History and Physical

Before evaluating a patient with agitation, clinicians should ensure the environment is safe. They should ensure they can access the room's exit without interference. Staff should remain nearby while the clinician examines the patient in case of behavioral escalation. Clinicians should maintain a safe distance of at least 1 to 2 arm's length from the patient. Maintaining a calm demeanor and empathic approach may help reduce the risk of aggression.[34][35][36]

Obtaining a history from an agitated individual can be difficult, as patients may be physically or verbally aggressive. Early recognition of risk is important, as are interventions targeted to the etiology of the agitation. The history and physical examination may first require nonpharmacological interventions (such as verbal de-escalation, changes in environment, and psychoeducation), medications, or physical restraint.

Before considering physical restraints or medications, clinicians should first ensure the safety of the surroundings and attempt verbal de-escalation. If possible, they should move the patient to a quiet room with lower stimuli and dimmer lights and away from loud areas.[37] Verbal de-escalation can be aided by using a calm and even tone of voice, respecting personal space, using one person with one message, naming feelings, and appealing to the patient's wants or needs. In addition, setting limits and reinforcing appropriate behavior may be necessary. If medications are required, offering a choice to patients regarding medications or route of administration may increase their sense of control and reduce anxiety. Some patients may respond to verbal de-escalation alone. After de-escalation, clinicians can attempt a focused evaluation, continuously monitoring for potential sudden outbursts of aggression during this process. They should avoid leading questions or making assumptions and initially focus on identifying the probable cause of the agitation.

If patients do not respond to verbal de-escalation, oral medication should be offered next if patient or staff safety is not threatened. Oral medication can help engage the patient in their care and reduce a sense of coercion. If possible, collateral information should be obtained from any accompanying family member, friend, or witness while the medication takes effect and the patient is given time and space. If the patient remains agitated despite oral medication, a locked or unlocked seclusion room may provide an additional reduction in stimuli. Physical restraint and intramuscular medication may be necessary if safety remains a concern. When using seclusion, physical restraint, or intramuscular medication, the patient should be monitored closely and reassessed when it is safe to complete the evaluation and treatment plan. 

In 2012, the American Association of Emergency Psychiatry Project BETA (Best Practices in the Evaluation and Treatment of Agitation in the emergency setting) published a consensus statement outlining recommendations for the medical evaluation and triage of patients with agitation,[38] which was updated in 2019 [39] and 2023.[37] Evaluating a patient with agitation differs based on whether the setting is nonmedical or medical. A brief history and vital signs should be obtained as safety allows.

Immediate assessment for serious, possibly life-threatening conditions is recommended next. Symptoms that require immediate evaluation by a clinician include loss of memory, disorientation, severe headache, extreme muscle stiffness or weakness, heat intolerance, unintentional weight loss, new-onset psychosis, or difficulty breathing. Signs that require immediate evaluation by a clinician include any abnormal vital signs (blood pressure, pulse, oxygen saturation, or temperature), abnormal point-of-care glucose, any overt trauma, pupil asymmetry, slurred speech, incoordination, seizures, or hemiparesis.[38] In a nonmedical setting, any of these signs or symptoms should lead to transfer to an emergency department or immediate clinician evaluation in a medical setting.

In a nonmedical setting, if none of the above symptoms or signs are identified, assessing the level of agitation is recommended using psychometric scales such as the Overt Agitation Severity Scale (OASS) or the Behavioral Activity Rating Scale (BARS). Various screening tools and psychometric scales are available, and the choice of tool may depend on factors such as workflow, ease of use, setting, time constraints, and patient population. No current consensus favors one screening tool over another. Project BETA utilized BARS as a scale to triage patients.[38] An individual who is difficult to arouse or cannot be aroused (BARS 1) should be transferred to a medical emergency department. If an individual does not respond to de-escalation, they should be moved to an acute care facility for further evaluation. If de-escalation is successful (BARS 5 or 6), or if the patient presents with a BARS of 4 and the presentation is consistent with their known psychiatric condition, routine management is recommended.

History should be obtained from the patient and collateral sources (family, law enforcement, emergency medical services, and outpatient providers). This history should include details about previous agitation or violence, prior psychiatric hospitalizations, TBI, cognitive problems, borderline or antisocial personality disorder, interpersonal violence, and substance use.[37]

The physical examination should include an assessment of the heart, lungs, abdomen, skin, and neurological system, as well as a mental status examination.[38] For agitation due to a general medical condition, the examination should focus on head trauma, slurred speech, pupil asymmetry, motor problems, seizures, disorientation, hemiparesis, somnolence, muscle rigidity, myoclonus, and hyperreflexia.[38] In cases of agitation due to alcohol or substance withdrawal or intoxication, the physical examination should assess for the odor of alcohol and evidence of drug injection, such as track marks, hallucinations, and seizures.[38]

Evaluation

Identifying the etiology of agitation is a priority. Initially, a point-of-care glucose test, oxygen saturation measurement, and urine toxicology screen are useful. In cases of suspected substance intoxication or withdrawal, additional tests should include a urine toxicology screen, blood alcohol level, and liver function tests. When delirium is suspected, a complete blood count, comprehensive metabolic panel, urinalysis, urine toxicology screen, and head CT scan should be obtained to determine the etiology of delirium so the underlying cause can be treated.

Other tests to consider include:

  • Pregnancy test: For all women of reproductive age.
  • Ammonia: For hepatic encephalopathy.
  • Creatinine kinase: For rhabdomyolysis, myopathy, and other muscle damage.
  • Thyroid-stimulating hormone (TSH): For hypothyroidism or hyperthyroidism.
  • Lactate: For sepsis.
  • Acetaminophen and salicylate levels: For overdose.
  • Urinalysis and urine culture: For urinary tract infection or ketosis.
  • Lumbar puncture: For encephalitis or meningitis, syphilis, or cerebritis.
  • Electrocardiogram (ECG): For QTc prolongation associated with overdose or cardiac disease.

Further laboratory testing and radiographic evaluation should be guided by the identified underlying etiology.[40] 

Treatment / Management

Treatment of an agitated patient should prioritize diagnosing and treating acute medical conditions while ensuring the safety of the patient, staff, and environment. Treatment recommendations should be guided by the underlying etiology of the agitation and the epidemiology of the local patient population.[41] This includes understanding the prevalence of specific substance use within the community and differentiating agitation resulting from intoxication or withdrawal.

The best way to engage agitated patients is through noncoercive de-escalation, a complex intervention at the interface of psychotherapy, linguistic sciences, martial arts, the nursing profession, and law enforcement.[42] Patients may respond better to a particular healthcare provider for various reasons, in which case that provider can either lead or help facilitate the evaluation. Helping the patient feel that their concerns are being heard and addressed, and reflecting the patient's statements in their own words, can convey that the clinician is listening. Open-ended questions and active listening may de-escalate a volatile situation. If verbal de-escalation does not work, offering voluntary oral medications may be the next step. Seclusion may help calm the patient if excess environmental stimuli contribute to agitation. Patients should be allowed to self-regulate whenever possible without medications or physical restraints.

In cases where all other interventions have failed or if patient or staff safety is threatened, involuntary medications may be necessary. When medications must be used, the goal should be to calm the patient so that they may safely engage in the medical evaluation. Clinicians should try to avoid sedating the patient if possible; however, treating for safety remains the primary goal. If a patient does experience sedation after medication administration, the patient should be closely monitored. Sedation from medications may also assist in recovery from agitation in specific cases, such as acute mania, which is a disorder of the sleep-wake cycle.[43] In more severely agitated patients, especially those actively trying to hurt themselves or others, sedation may be emergently necessary. Using intramuscular injections for sedation can be termed a "chemical restraint" and is controversial.[9][44]

If agitation is mild or moderate, allowing the patient a choice regarding medication options may help reduce agitation. Oral medication administration should be prioritized over parenteral administration, although oral medications take effect more slowly. Institutions may have guidelines for the use of preferred medications. Agitation secondary to alcohol intoxication is best treated with an antipsychotic medication, whereas agitation secondary to alcohol withdrawal is best treated with a benzodiazepine. Evidence suggests that patients with neurocognitive disorders with agitation benefit from group activity-based interventions (recreation therapy), resident interventions (massage and touch therapy and music therapy), and person-centered care.[45]  

If a patient is a danger to themselves or others, they may require physical restraints. When physical restraints are implemented, close monitoring of the patient is necessary to ensure safety. Traumatic rhabdomyolysis has been associated with prolonged physical restraints, especially in individuals actively fighting against the restraints.[46] In these cases, administering medications along with physical restraints may reduce the length of time restraints are needed and the subsequent risk of rhabdomyolysis. Other risks of physical restraints include pressure ulcers, asphyxiation, nerve and limb injuries, head injuries and intracranial hemorrhage, contractures, posttraumatic stress disorder, and reinforcement of past psychological traumas.[47] Physical restraints may also induce hostility from the patient toward staff and contribute to future aggression. Patients who are restrained are more likely to have longer lengths of stay, increased risk of falls, decline in physical function, and increased risk of psychiatric comorbidities.[48] Physical restraints are the last resort and should be avoided if possible.

Pharmacological Management of Severe Agitation

The 2024 American College of Emergency Physicians (ACEP) evidence-based clinical policy for the treatment of patients in the emergency department with severe agitation recommends treatment with a combination of droperidol and midazolam or an atypical antipsychotic medication in combination with midazolam (Level B recommendation). The ACEP also recommends haloperidol alone or in combination with lorazepam (Level B recommendation).[49] Midazolam appears to have a more rapid onset than lorazepam. Olanzapine may have a more favorable profile than other atypical antipsychotic medications but should not be administered with benzodiazepines due to the risk of hypotension, bradycardia, and respiratory depression.[49] In situations in the emergency department where the safety of the patient, bystanders, or staff is a concern, the ACEP recommends considering intravenous or intramuscular ketamine to rapidly treat severe agitation (Level C recommendation), noting the risks of laryngospasm and hypersalivation with an infrequent need for intubation due to these adverse effects.[49]

According to the ACEP review, due to the lack of evidence, no recommendations can be made regarding the use of specific agents in out-of-hospital settings or for patients aged 65 or older.[49] Both typical and atypical antipsychotic medications have black box warnings indicating that elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. The ACEP acknowledges that droperidol carries a black box warning for QT prolongation, requiring ECG monitoring of the QT interval before administration and continuing for 2 to 3 hours after completing treatment. However, the ACEP review demonstrated an overall favorable safety profile for droperidol when used for sedation of agitated patients in the emergency department.[49]

The Society of Critical Care Medicine (SCCM) 2018 Practice Guidelines suggest not routinely using haloperidol to treat delirium, as the evidence indicates that the use of haloperidol or an atypical antipsychotic medication is not associated with a shorter duration of delirium, mechanical ventilation, ICU length of stay, or decreased mortality. Despite the lack of evidence, short-term use of haloperidol or an atypical antipsychotic medication may be considered for agitated patients who may physically harm themselves or others. The SCCM conditionally recommends using dexmedetomidine for delirium in mechanically ventilated adults where agitation is precluding weaning/extubation.[35]  

The American Psychiatric Association (APA) Practice Guideline (2016) recommends considering nonemergency antipsychotic medication only for managing "severe, dangerous, and/or significantly distressing agitation or psychosis."[50] In addition, the APA recommends reviewing the clinical response to nonpharmacological interventions before using nonemergency antipsychotics for agitation and constantly assessing the benefit-to-harm ratio.

Identifying drugs that may contribute to agitation is the first step in the pharmacological treatment of patients with neurocognitive disorders. Anticholinergic drugs may cause delirium, antipsychotic medications may cause neuroleptic malignant syndrome, serotonergic drugs may cause serotonin syndrome, and stimulants may cause hyperarousal. Cholinesterase inhibitors and memantine may reduce agitation in people with Alzheimer disease or Lewy body disease.[45]

The International Psychogeriatric Association (IPA) consensus algorithm (2024) emphasizes the importance of ongoing psychosocial interventions for patients with neurocognitive disorders and agitation. IPA suggests various pharmacological treatments based on severity and circumstances, noting that there are no FDA-approved medications specifically for agitation in the United States.[45] Agitation that occurs at night or with "sundowning" can be treated with trazodone or dual orexin receptor antagonists such as suvorexant and lemborexant. Mild-to-moderate agitation or agitation with mood features can be treated with citalopram. In contrast, moderate-to-severe agitation can be treated with atypical antipsychotic medications (avoided in patients with Lewy body disease or Parkinson disease), carbamazepine, gabapentin, prazosin, dextromethorphan/quinidine, nabilone, or a combination of these medications. If agitation is extreme, intramuscular olanzapine or aripiprazole, or electroconvulsive therapy can reduce agitation. For patients with neurocognitive disorders with pain, such as hospice patients, morphine, delta-9-tetracannabinol, dronabinol, and cannabidiol can be beneficial.[45]    

Benzodiazepines are the first-line therapy for agitated patients with alcohol withdrawal or central nervous system stimulant toxicity from cocaine or amphetamines.[41] The American Society of Addiction Medicine (ASAM) recommends avoiding antipsychotic monotherapy for agitation in alcohol withdrawal, as it may lead to delirium tremens and an increased risk of complicated withdrawal.[51] Antipsychotic medications also reduce the seizure threshold.[52] The World Federation of Societies of Biological Psychiatry (WFSBP) recommends that for agitation associated with alcohol intoxication rather than withdrawal, antipsychotics are preferred over benzodiazepines, which can potentiate the effects of alcohol and increase the risk of respiratory depression.[41]

In patients with autism spectrum disorder and agitation, risperidone and aripiprazole are the only FDA-approved medications.[53] Both medications have been studied primarily in children and adolescents, and further research is needed to confirm their effectiveness. Risperidone was approved by the FDA in 2007 for patients aged 5 to 17, following short-term trials demonstrating benefits in reducing aggression, self-injury, temper tantrums, and mood swings, with over 90% of participants aged 12 or younger. Aripiprazole is also FDA-approved for treating irritability associated with autism spectrum disorder in children and adolescents aged 6 to 17.

Differential Diagnosis

The differential diagnoses of agitation can be broadly classified as physical illness and delirium, neurocognitive disorders, substance use and withdrawal, and psychiatric and developmental conditions (see Table below).[54]

Table. Examples of Differential Diagnoses of Agitation

System

Differential Diagnosis

Constitutional

Insomnia, pain, hypothermia, hyperthermia, and terminal illness.

Neurological

TBI, neurocognitive disorders, intracranial hemorrhage, stroke, transient ischemic attack, encephalopathy, epilepsy, autoimmune encephalitis, and seizure.

Infectious

Meningitis, encephalitis, sepsis, urinary tract infection, pneumonia, cellulitis, and necrotizing fasciitis.

Cardiopulmonary 

Myocardial infarction, heart failure, arrhythmia, pulmonary embolism, respiratory failure, hypoxia, and hypoxemia.

Metabolic and endocrine

Diabetic ketoacidosis, electrolyte disturbances, chronic malnutrition, hypoglycemia, hyperthyroidism, myxedema, and hyperparathyroidism.

Gastrointestinal 

Ileus, inflammatory bowel disease, gastrointestinal obstruction, and constipation.

Toxicological

Environmental toxins and medication-related adverse effects, including anticholinergic medications, akathisia, cholinergic toxicity, neuroleptic malignant syndrome, serotonin syndrome, and medication interactions, and polypharmacy.

Hematologic and Oncologic

Anemia, leukemia, multiple myeloma, primary brain tumors, brain metastases, and paraneoplastic syndrome.

Renal

Acute and chronic kidney disease, end-stage renal disease, including non-adherence to dialysis, and uremia.

Psychiatric

Acute psychosis from schizophrenia spectrum disorders, acute mania from bipolar spectrum disorders, agitated depression, excited catatonia, anxiety and panic disorders, acute exacerbation of posttraumatic stress disorder, personality disorders, conduct disorder, attention-deficit/hyperactivity disorder, intermittent explosive disorder, dissociative disorder, and postpartum psychosis.

Substance

Substance intoxication (alcohol, cannabis, cocaine, stimulants, hallucinogens, and inhalants), substance withdrawal (nicotine, alcohol, benzodiazepines, and barbituates), and Wernicke-Korsakoff syndrome. 

Reference for the Table.[37]

Prognosis

Agitation is a medical and psychiatric emergency with a broad differential diagnosis. The prognosis depends on the swift identification of the underlying cause, prompt treatment, and maintaining a safe environment to prevent injury to patients, bystanders, and staff. In the short term, reducing stress, improving sleep quality, and addressing the patient's needs can often lead to better outcomes. Agitation related to substance use may resolve with detoxification and treatment of withdrawal symptoms. Patients with altered mental status who exhibit generalized slowing on electroencephalogram may have a worse prognosis.[55] In the ICU, agitated patients with delirium tend to have a worse prognosis compared to those without agitation.[56]

Complications

Agitation is a medical and psychiatric emergency that heightens the risk of injury to patients, bystanders, and staff. Complications associated with agitation include falls, removal of indwelling catheters and tubes, and restraint-related injuries. Physical restraints can lead to dislocations, fractures, skin abrasions, head injuries, and rhabdomyolysis, especially if individuals remain agitated and resist the restraints. The use of sedating medications in conjunction with physical restraints can help mitigate these risks.

Deterrence and Patient Education

Patient education after an acute agitation episode can help patients understand the underlying causes and potentially reduce future risks. The effectiveness of patient education varies depending on the etiology of the agitation. Major neurocognitive disorders, autism spectrum disorders, and delirium may not be easily preventable through patient education alone, as agitation can recur due to chronic medical issues and frontal lobe dysfunction. However, outpatient behavioral interventions and treatments can help mitigate agitation and aggression in patients with autism spectrum disorders.[57] 

For individuals with psychiatric disorders such as schizophrenia, bipolar disorder, and substance use disorders, patient education should focus on the importance of treatment compliance and provide detailed information about medications. For individuals with personality disorders, debriefing the causes of emotional dysregulation and using techniques such as behavioral chain analysis to identify predisposing, precipitating, perpetuating, and protective factors can help patients reflect on the episode systematically and develop strategies to prevent future occurrences.

Pearls and Other Issues

Key considerations regarding agitation include:

  • Agitation is a medical and psychiatric emergency that increases the risk of injury to patients, bystanders, and staff.
  • Management should prioritize diagnosing and treating acute medical conditions while ensuring the safety of the patient, staff, and environment.
  • Collateral information should be collected to help identify the underlying cause of agitation.
  • Verbal de-escalation and minimizing environmental stimuli are initial steps in managing agitation.
  • If calming medications are required, clinicians should involve the patient in choosing the medication and route of administration to enhance their sense of control.
  • Medications and seclusion are the next steps in treating individuals with severe agitation.
  • Physical restraints should be avoided unless essential for the safety of the patient, bystanders, and staff.
  • When required, physical restraints should be used for the minimal time necessary. The patient should be monitored closely, and efforts should be made to transition them to a less restrictive approach as soon as possible.
  • Agitation management, including the use of calming medications, should be tailored to the individual, the setting, and the underlying etiology.
  • Both the adverse and beneficial effects of medications should be closely monitored to ensure patient safety and optimize outcomes. 

Enhancing Healthcare Team Outcomes

Multidisciplinary treatment teams should ideally be trained in safely managing agitation and assaultive behaviors with minimal necessary interventions.[58][59] Nonviolent crisis intervention techniques have been associated with a reduction in emergency security team involvement.[60] Additionally, training in the management of agitation may improve the likelihood of staff being able to complete thorough assessments of these challenging patients.[61][62]

The most effective approach to engaging agitated patients is through noncoercive de-escalation, a multifaceted intervention that combines elements of psychotherapy, linguistic sciences, martial arts, nursing, and law enforcement.[42] Clinicians can enhance these skills by role-playing and practicing impromptu scenarios with colleagues, with further refinement gained through real-world experience. Because the definition and use of the term "agitation" can vary, the clinical team should identify patient-specific behaviors to clarify how agitation is defined for that particular patient. Achieving consensus on this definition will help guide the management plan effectively.[3] 

Agitation is common among hospitalized patients and requires a collaborative approach from the multidisciplinary team. The interprofessional healthcare team should include psychiatry, internal medicine, physician assistants, nurse practitioners, nursing and nursing assistants, neurology, applicable medical subspecialists, pharmacists, and hospital security. The involvement of a multidisciplinary healthcare team is essential in rapport building, de-escalation, limit setting, medication administration, and ongoing assessment of the value of various interventions. Only team members trained in physical crisis intervention should attempt to intervene if physical force is necessary. Following the treatment of an agitated patient, the team should debrief to process emotions about the situation, identify patterns in patient behavior, and discuss strategies for improving ongoing treatment.


Details

Updated:

7/30/2024 3:55:21 AM

Looking for an easier read?

Click here for a simplified version

References


[1]

Pompili M, Ducci G, Galluzzo A, Rosso G, Palumbo C, De Berardis D. The Management of Psychomotor Agitation Associated with Schizophrenia or Bipolar Disorder: A Brief Review. International journal of environmental research and public health. 2021 Apr 20:18(8):. doi: 10.3390/ijerph18084368. Epub 2021 Apr 20     [PubMed PMID: 33924111]


[2]

Martínez-Raga J, Amore M, Di Sciascio G, Florea RI, Garriga M, Gonzalez G, Kahl KG, Karlsson PA, Kuhn J, Margariti M, Pacciardi B, Papageorgiou K, Pompili M, Rivollier F, Royuela Á, Safont G, Scharfetter J, Skagen B, Tajima-Pozo K, Vidailhet P. 1st International Experts' Meeting on Agitation: Conclusions Regarding the Current and Ideal Management Paradigm of Agitation. Frontiers in psychiatry. 2018:9():54. doi: 10.3389/fpsyt.2018.00054. Epub 2018 Feb 27     [PubMed PMID: 29535649]


[3]

Wolf MU, Goldberg Y, Freedman M. Aggression and Agitation in Dementia. Continuum (Minneapolis, Minn.). 2018 Jun:24(3, BEHAVIORAL NEUROLOGY AND PSYCHIATRY):783-803. doi: 10.1212/CON.0000000000000605. Epub     [PubMed PMID: 29851878]


[4]

Miller J. Managing acute agitation and aggression in the world of drug shortages. The mental health clinician. 2021 Nov:11(6):334-346. doi: 10.9740/mhc.2021.11.334. Epub 2021 Nov 8     [PubMed PMID: 34824958]


[5]

Keene J, Hope T, Fairburn CG, Jacoby R, Gedling K, Ware CJ. Natural history of aggressive behaviour in dementia. International journal of geriatric psychiatry. 1999 Jul:14(7):541-8     [PubMed PMID: 10440974]


[6]

Mitolo M, Tonon C, La Morgia C, Testa C, Carelli V, Lodi R. Effects of Light Treatment on Sleep, Cognition, Mood, and Behavior in Alzheimer's Disease: A Systematic Review. Dementia and geriatric cognitive disorders. 2018:46(5-6):371-384. doi: 10.1159/000494921. Epub 2018 Dec 11     [PubMed PMID: 30537760]

Level 1 (high-level) evidence

[7]

Urner M, Ferreyro BL, Douflé G, Mehta S. Supportive Care of Patients on Mechanical Ventilation. Respiratory care. 2018 Dec:63(12):1567-1574. doi: 10.4187/respcare.06651. Epub     [PubMed PMID: 30467227]


[8]

Haskell RM, Frankel HL, Rotondo MF. Agitation. AACN clinical issues. 1997 Aug:8(3):335-50     [PubMed PMID: 9313372]


[9]

Miner JR, Klein LR, Cole JB, Driver BE, Moore JC, Ho JD. The Characteristics and Prevalence of Agitation in an Urban County Emergency Department. Annals of emergency medicine. 2018 Oct:72(4):361-370. doi: 10.1016/j.annemergmed.2018.06.001. Epub 2018 Jul 19     [PubMed PMID: 30031556]


[10]

Ramírez Echeverría MDL, Schoo C, Paul M. Delirium. StatPearls. 2024 Jan:():     [PubMed PMID: 29261982]


[11]

Silić A, Savić A, Čulo I, Kos S, Vukojević J, Brumen D, Ostojić D. Approach to Emergencies in Schizophrenia in University Hospital "Vrapče". Psychiatria Danubina. 2018 Jun:30(Suppl 4):203-207     [PubMed PMID: 29864761]


[12]

Séguin JR. The frontal lobe and aggression. The European journal of developmental psychology. 2009 Jan 5:6(1):100-119     [PubMed PMID: 24976846]


[13]

Brower MC, Price BH. Neuropsychiatry of frontal lobe dysfunction in violent and criminal behaviour: a critical review. Journal of neurology, neurosurgery, and psychiatry. 2001 Dec:71(6):720-6     [PubMed PMID: 11723190]


[14]

Pajonk FG, Schmitt P, Biedler A, Richter JC, Meyer W, Luiz T, Madler C. Psychiatric emergencies in prehospital emergency medical systems: a prospective comparison of two urban settings. General hospital psychiatry. 2008 Jul-Aug:30(4):360-6. doi: 10.1016/j.genhosppsych.2008.03.005. Epub     [PubMed PMID: 18585541]


[15]

Carrarini C, Russo M, Dono F, Barbone F, Rispoli MG, Ferri L, Di Pietro M, Digiovanni A, Ajdinaj P, Speranza R, Granzotto A, Frazzini V, Thomas A, Pilotto A, Padovani A, Onofrj M, Sensi SL, Bonanni L. Agitation and Dementia: Prevention and Treatment Strategies in Acute and Chronic Conditions. Frontiers in neurology. 2021:12():644317. doi: 10.3389/fneur.2021.644317. Epub 2021 Apr 16     [PubMed PMID: 33935943]

Level 3 (low-level) evidence

[16]

Bauhuis R, Mulders AJMJ, Koopmans RTCM. The course of neuropsychiatric symptoms in institutionalized patients with young onset dementia. Aging & mental health. 2020 Mar:24(3):439-444. doi: 10.1080/13607863.2018.1531379. Epub 2018 Nov 30     [PubMed PMID: 30499335]


[17]

Arroyo-Novoa CM, Figueroa-Ramos MI, Puntillo KA. Occurrence and Practices for Pain, Agitation, and Delirium in Intensive Care Unit Patients. Puerto Rico health sciences journal. 2019 Sep:38(3):156-162     [PubMed PMID: 31536628]


[18]

Burk RS, Grap MJ, Munro CL, Schubert CM, Sessler CN. Agitation onset, frequency, and associated temporal factors in critically ill adults. American journal of critical care : an official publication, American Association of Critical-Care Nurses. 2014 Jul:23(4):296-304. doi: 10.4037/ajcc2014186. Epub     [PubMed PMID: 24986170]


[19]

Jaber S, Chanques G, Altairac C, Sebbane M, Vergne C, Perrigault PF, Eledjam JJ. A prospective study of agitation in a medical-surgical ICU: incidence, risk factors, and outcomes. Chest. 2005 Oct:128(4):2749-57     [PubMed PMID: 16236951]


[20]

Roberts J, Gracia Canales A, Blanthorn-Hazell S, Craciun Boldeanu A, Judge D. Characterizing the experience of agitation in patients with bipolar disorder and schizophrenia. BMC psychiatry. 2018 Apr 16:18(1):104. doi: 10.1186/s12888-018-1673-3. Epub 2018 Apr 16     [PubMed PMID: 29661160]


[21]

Theriault KM, Rosenheck RA, Rhee TG. Increasing Emergency Department Visits for Mental Health Conditions in the United States. The Journal of clinical psychiatry. 2020 Jul 28:81(5):. pii: 20m13241. doi: 10.4088/JCP.20m13241. Epub 2020 Jul 28     [PubMed PMID: 32726001]


[22]

Sachs GS. A review of agitation in mental illness: burden of illness and underlying pathology. The Journal of clinical psychiatry. 2006:67 Suppl 10():5-12     [PubMed PMID: 16965190]


[23]

Zhong S, Yu R, Fazel S. Drug Use Disorders and Violence: Associations With Individual Drug Categories. Epidemiologic reviews. 2020 Jan 31:42(1):103-116. doi: 10.1093/epirev/mxaa006. Epub     [PubMed PMID: 33005950]


[24]

Williamson DR, Frenette AJ, Burry L, Perreault MM, Charbonney E, Lamontagne F, Potvin MJ, Giguère JF, Mehta S, Bernard F. Pharmacological interventions for agitation in patients with traumatic brain injury: protocol for a systematic review and meta-analysis. Systematic reviews. 2016 Nov 17:5(1):193     [PubMed PMID: 27855720]

Level 1 (high-level) evidence

[25]

Smith J, Baksh RA, Hassiotis A, Sheehan R, Ke C, Wong TLB, PETAL Investigators, Strydom A. Aggressive challenging behavior in adults with intellectual disability: An electronic register-based cohort study of clinical outcome and service use. European psychiatry : the journal of the Association of European Psychiatrists. 2022 Nov 2:65(1):e74. doi: 10.1192/j.eurpsy.2022.2336. Epub 2022 Nov 2     [PubMed PMID: 36321353]

Level 2 (mid-level) evidence

[26]

Delli Pizzi S, Padulo C, Brancucci A, Bubbico G, Edden RA, Ferretti A, Franciotti R, Manippa V, Marzoli D, Onofrj M, Sepede G, Tartaro A, Tommasi L, Puglisi-Allegra S, Bonanni L. GABA content within the ventromedial prefrontal cortex is related to trait anxiety. Social cognitive and affective neuroscience. 2016 May:11(5):758-66. doi: 10.1093/scan/nsv155. Epub 2015 Dec 31     [PubMed PMID: 26722018]


[27]

Goyer PF, Andreason PJ, Semple WE, Clayton AH, King AC, Compton-Toth BA, Schulz SC, Cohen RM. Positron-emission tomography and personality disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 1994 Feb:10(1):21-8     [PubMed PMID: 8179791]


[28]

Lindenmayer JP. The pathophysiology of agitation. The Journal of clinical psychiatry. 2000:61 Suppl 14():5-10     [PubMed PMID: 11154018]


[29]

Miller CWT, Hodzic V, Weintraub E. Current Understanding of the Neurobiology of Agitation. The western journal of emergency medicine. 2020 Jul 2:21(4):841-848. doi: 10.5811/westjem.2020.4.45779. Epub 2020 Jul 2     [PubMed PMID: 32726254]

Level 3 (low-level) evidence

[30]

Siever L, Trestman RL. The serotonin system and aggressive personality disorder. International clinical psychopharmacology. 1993 Nov:8 Suppl 2():33-9     [PubMed PMID: 8201245]


[31]

New AS, Trestman RL, Mitropoulou V, Benishay DS, Coccaro E, Silverman J, Siever LJ. Serotonergic function and self-injurious behavior in personality disorder patients. Psychiatry research. 1997 Mar 3:69(1):17-26     [PubMed PMID: 9080541]


[32]

Geniole SN, Bird BM, McVittie JS, Purcell RB, Archer J, Carré JM. Is testosterone linked to human aggression? A meta-analytic examination of the relationship between baseline, dynamic, and manipulated testosterone on human aggression. Hormones and behavior. 2020 Jul:123():104644. doi: 10.1016/j.yhbeh.2019.104644. Epub 2019 Dec 28     [PubMed PMID: 31785281]


[33]

Musco S, McAllister V, Caudle I. Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment. Therapeutic advances in psychopharmacology. 2020:10():2045125320937575. doi: 10.1177/2045125320937575. Epub 2020 Aug 27     [PubMed PMID: 32922732]

Level 3 (low-level) evidence

[34]

Maximous R, Miller F, Tan C, Camargo M, Ross K, Marshall C, Yung P, Fleming D, Law M, Tsang JLY. Pain, agitation and delirium assessment and management in a community medical-surgical ICU: results from a prospective observational study and nurse survey. BMJ open quality. 2018:7(4):e000413. doi: 10.1136/bmjoq-2018-000413. Epub 2018 Oct 15     [PubMed PMID: 30397663]

Level 2 (mid-level) evidence

[35]

Devlin JW, Skrobik Y, Gélinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, Balas MC, van den Boogaard M, Bosma KJ, Brummel NE, Chanques G, Denehy L, Drouot X, Fraser GL, Harris JE, Joffe AM, Kho ME, Kress JP, Lanphere JA, McKinley S, Neufeld KJ, Pisani MA, Payen JF, Pun BT, Puntillo KA, Riker RR, Robinson BRH, Shehabi Y, Szumita PM, Winkelman C, Centofanti JE, Price C, Nikayin S, Misak CJ, Flood PD, Kiedrowski K, Alhazzani W. Executive Summary: Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Critical care medicine. 2018 Sep:46(9):1532-1548. doi: 10.1097/CCM.0000000000003259. Epub     [PubMed PMID: 30113371]

Level 1 (high-level) evidence

[36]

Souza TL, Azzolin KO, Fernandes VR. Multiprofessional care for delirium patients in intensive care: integrative review. Revista gaucha de enfermagem. 2018 Aug 2:39():e20170157. doi: 10.1590/1983-1447.2018.2017-0157. Epub 2018 Aug 2     [PubMed PMID: 30088606]


[37]

Curry A, Malas N, Mroczkowski M, Hong V, Nordstrom K, Terrell C. Updates in the Assessment and Management of Agitation. Focus (American Psychiatric Publishing). 2023 Jan:21(1):35-45. doi: 10.1176/appi.focus.20220064. Epub 2023 Jan 16     [PubMed PMID: 37205032]


[38]

Nordstrom K, Zun LS, Wilson MP, Stiebel V, Ng AT, Bregman B, Anderson EL. Medical evaluation and triage of the agitated patient: consensus statement of the american association for emergency psychiatry project Beta medical evaluation workgroup. The western journal of emergency medicine. 2012 Feb:13(1):3-10. doi: 10.5811/westjem.2011.9.6863. Epub     [PubMed PMID: 22461915]

Level 3 (low-level) evidence

[39]

Roppolo LP, Morris DW, Khan F, Downs R, Metzger J, Carder T, Wong AH, Wilson MP. Improving the management of acutely agitated patients in the emergency department through implementation of Project BETA (Best Practices in the Evaluation and Treatment of Agitation). Journal of the American College of Emergency Physicians open. 2020 Oct:1(5):898-907. doi: 10.1002/emp2.12138. Epub 2020 Jul 3     [PubMed PMID: 33145538]


[40]

Zeller SL, Rhoades RW. Systematic reviews of assessment measures and pharmacologic treatments for agitation. Clinical therapeutics. 2010 Mar:32(3):403-25. doi: 10.1016/j.clinthera.2010.03.006. Epub     [PubMed PMID: 20399981]

Level 1 (high-level) evidence

[41]

Searles Quick VB, Herbst ED, Kalapatapu RK. Which Emergent Medication Should I Give Next? Repeated Use of Emergent Medications to Treat Acute Agitation. Frontiers in psychiatry. 2021:12():750686. doi: 10.3389/fpsyt.2021.750686. Epub 2021 Dec 7     [PubMed PMID: 34950067]


[42]

Richmond JS, Berlin JS, Fishkind AB, Holloman GH Jr, Zeller SL, Wilson MP, Rifai MA, Ng AT. Verbal De-escalation of the Agitated Patient: Consensus Statement of the American Association for Emergency Psychiatry Project BETA De-escalation Workgroup. The western journal of emergency medicine. 2012 Feb:13(1):17-25. doi: 10.5811/westjem.2011.9.6864. Epub     [PubMed PMID: 22461917]

Level 3 (low-level) evidence

[43]

Goodwin GM, Abbar M, Schlaepfer TE, Grunze H, Licht RW, Bellivier F, Fountoulakis KN, Altamura AC, Pitchot W, Ågren H, Holsboer-Trachsler E, Vieta E. Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance. Current medical research and opinion. 2011 Dec:27(12):2285-99. doi: 10.1185/03007995.2011.628380. Epub 2011 Oct 21     [PubMed PMID: 22014287]

Level 3 (low-level) evidence

[44]

Currier GW. The controversy over "chemical restraint" in acute care psychiatry. Journal of psychiatric practice. 2003 Jan:9(1):59-70     [PubMed PMID: 15985915]

Level 3 (low-level) evidence

[45]

Cummings J, Sano M, Auer S, Bergh S, Fischer CE, Gerritsen D, Grossberg G, Ismail Z, Lanctôt K, Lapid MI, Mintzer J, Palm R, Rosenberg PB, Splaine M, Zhong K, Zhu CW. Reduction and prevention of agitation in persons with neurocognitive disorders: an international psychogeriatric association consensus algorithm. International psychogeriatrics. 2024 Apr:36(4):251-262. doi: 10.1017/S104161022200103X. Epub 2023 Mar 6     [PubMed PMID: 36876335]

Level 3 (low-level) evidence

[46]

Huerta-Alardín AL, Varon J, Marik PE. Bench-to-bedside review: Rhabdomyolysis -- an overview for clinicians. Critical care (London, England). 2005 Apr:9(2):158-69     [PubMed PMID: 15774072]

Level 3 (low-level) evidence

[47]

Gunawardena R, Smithard DG. The Attitudes Towards the Use of Restraint and Restrictive Intervention Amongst Healthcare Staff on Acute Medical and Frailty Wards-A Brief Literature Review. Geriatrics (Basel, Switzerland). 2019 Sep 4:4(3):. doi: 10.3390/geriatrics4030050. Epub 2019 Sep 4     [PubMed PMID: 31487923]


[48]

Spennato U, Lerjen N, Siegwart J, Mueller B, Schuetz P, Koch D, Struja T. Prevalence, Risk Factors and Outcomes Associated with Physical Restraint in Acute Medical Inpatients over 4 Years-A Retrospective Cohort Study. Geriatrics (Basel, Switzerland). 2023 Jan 17:8(1):. doi: 10.3390/geriatrics8010015. Epub 2023 Jan 17     [PubMed PMID: 36826357]

Level 2 (mid-level) evidence

[49]

American College of Emergency Physicians Clinical Policies Subcommittee (Writing Committee) on Severe Agitation, Thiessen MEW, Godwin SA, Hatten BW, Whittle JA, Haukoos JS, Diercks DB, Members of the American College of Emergency Physicians Clinical Policies Committee (Oversight Committee), Diercks DB, Wolf SJ, Anderson JD, Byyny R, Carpenter CR, Friedman B, Gemme SR, Gerardo CJ, Godwin SA, Hahn SA, Hatten BW, Haukoos JS, Kaji A, Kwok H, Lo BM, Mace SE, Moran M, Promes SB, Shah KH, Shih RD, Silvers SM, Slivinski A, Smith MD, Thiessen MEW, Tomaszewski CA, Valente JH, Wall SP, Westafer LM, Yu Y, Cantrill SV, Finnell JT, Schulz T, Vandertulip K. Clinical Policy: Critical Issues in the Evaluation and Management of Adult Out-of-Hospital or Emergency Department Patients Presenting With Severe Agitation: Approved by the ACEP Board of Directors, October 6, 2023. Annals of emergency medicine. 2024 Jan:83(1):e1-e30. doi: 10.1016/j.annemergmed.2023.09.010. Epub     [PubMed PMID: 38105109]


[50]

Reus VI, Fochtmann LJ, Eyler AE, Hilty DM, Horvitz-Lennon M, Jibson MD, Lopez OL, Mahoney J, Pasic J, Tan ZS, Wills CD, Rhoads R, Yager J. The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia. The American journal of psychiatry. 2016 May 1:173(5):543-6. doi: 10.1176/appi.ajp.2015.173501. Epub     [PubMed PMID: 27133416]

Level 1 (high-level) evidence

[51]

. The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management. Journal of addiction medicine. 2020 May/Jun:14(3S Suppl 1):1-72. doi: 10.1097/ADM.0000000000000668. Epub     [PubMed PMID: 32511109]

Level 1 (high-level) evidence

[52]

Faustmann TJ, Paschali M, Kojda G, Schilbach L, Kamp D. [Antipsychotic Treatment of Alcohol Withdrawal Syndrome with Focus on Delirium Tremens: a Systematic Review]. Fortschritte der Neurologie-Psychiatrie. 2023 Mar 23:():. doi: 10.1055/a-2029-6387. Epub 2023 Mar 23     [PubMed PMID: 36958342]

Level 1 (high-level) evidence

[53]

Subramanyam AA, Mukherjee A, Dave M, Chavda K. Clinical Practice Guidelines for Autism Spectrum Disorders. Indian journal of psychiatry. 2019 Jan:61(Suppl 2):254-269. doi: 10.4103/psychiatry.IndianJPsychiatry_542_18. Epub     [PubMed PMID: 30745701]

Level 1 (high-level) evidence

[54]

Raveesh BN, Munoli RN, Gowda GS. Assessment and Management of Agitation in Consultation-Liaison Psychiatry. Indian journal of psychiatry. 2022 Mar:64(Suppl 2):S484-S498. doi: 10.4103/indianjpsychiatry.indianjpsychiatry_22_22. Epub 2022 Mar 23     [PubMed PMID: 35602364]


[55]

Kimchi EY, Neelagiri A, Whitt W, Sagi AR, Ryan SL, Gadbois G, Groothuysen D, Westover MB. Clinical EEG slowing correlates with delirium severity and predicts poor clinical outcomes. Neurology. 2019 Sep 24:93(13):e1260-e1271. doi: 10.1212/WNL.0000000000008164. Epub 2019 Aug 29     [PubMed PMID: 31467255]

Level 2 (mid-level) evidence

[56]

Chevrolet JC, Jolliet P. Clinical review: agitation and delirium in the critically ill--significance and management. Critical care (London, England). 2007:11(3):214     [PubMed PMID: 17521456]


[57]

Fitzpatrick SE, Srivorakiat L, Wink LK, Pedapati EV, Erickson CA. Aggression in autism spectrum disorder: presentation and treatment options. Neuropsychiatric disease and treatment. 2016:12():1525-38. doi: 10.2147/NDT.S84585. Epub 2016 Jun 23     [PubMed PMID: 27382295]


[58]

Calabro K, Mackey TA, Williams S. Evaluation of training designed to prevent and manage patient violence. Issues in mental health nursing. 2002 Jan-Feb:23(1):3-15     [PubMed PMID: 11887608]


[59]

Axer A, Beckett R. [Training in preventing assaultive behaviors for psychiatric professionals]. Psychiatria polska. 1998 Jul-Aug:32(4):433-41     [PubMed PMID: 9816901]


[60]

Gillam SW. Nonviolent crisis intervention training and the incidence of violent events in a large hospital emergency department: an observational quality improvement study. Advanced emergency nursing journal. 2014 Apr-Jun:36(2):177-88. doi: 10.1097/TME.0000000000000019. Epub     [PubMed PMID: 24785670]

Level 2 (mid-level) evidence

[61]

Anderson KE, van Duijn E, Craufurd D, Drazinic C, Edmondson M, Goodman N, van Kammen D, Loy C, Priller J, Goodman LV. Clinical Management of Neuropsychiatric Symptoms of Huntington Disease: Expert-Based Consensus Guidelines on Agitation, Anxiety, Apathy, Psychosis and Sleep Disorders. Journal of Huntington's disease. 2018:7(3):355-366. doi: 10.3233/JHD-180293. Epub     [PubMed PMID: 30040737]

Level 3 (low-level) evidence

[62]

Lofchy J. Agitation and CANMAT and ISBD 2018 Bipolar Guidelines. Bipolar disorders. 2018 Jul 18:():. doi: 10.1111/bdi.12687. Epub 2018 Jul 18     [PubMed PMID: 30022579]